Lytgobi Alternatives Compared
| Lytgobi (futibatinib) | Pemigatinib | Pemazyre (pemigatinib) |
|
|---|
| Lytgobi (futibatinib) | Pemigatinib | Pemazyre (pemigatinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cholangiocarcinoma. Lytgobi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cholangiocarcinoma, Myeloid/Lymphoid Neoplasms. Pemigatinib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cholangiocarcinoma, Myeloid/Lymphoid Neoplasms. Pemazyre may also be used for purposes not listed in this medication guide. |
Related suggestions Cholangiocarcinoma
|
|||||||||||||||
| More about Lytgobi (futibatinib) | More about Pemigatinib | More about Pemazyre (pemigatinib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Pemigatinib has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Pemazyre has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Lytgobi side effects |
View all Pemigatinib side effects |
View all Pemazyre side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Lytgobi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Pemazyre prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
Pemazyre |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
2.9 hours |
15.4 hours |
15.4 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 175 drugs are known to interact with Lytgobi:
|
A total of 293 drugs are known to interact with Pemigatinib:
|
A total of 293 drugs are known to interact with Pemazyre:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
April 17, 2020 |
April 17, 2020 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.